SCHEMBL15859875

SCHEMBL15859875

COC(=O)c1cc2cc(NCc3cccc(NC(=O)c4ccc(CN5CCN(C)CC5)c(C(F)(F)F)c4)c3)cnc2[nH]1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 9/20 0.56
▸ EGFR P00533 4/20 0.56
▸ BRAF P15056 4/20 0.56
▸ SRC P12931 1/20 0.56
▸ MAPK14 Q16539 1/20 0.55
▸ MAP3K20 Q9NYL2 1/20 0.55
▸ RET P07949 3/20 0.52
▸ CSF1R P07333 1/20 0.52
▸ DDR1 Q08345 1/20 0.51
▸ BCR P11274 2/20 0.51
▸ KIT P10721 1/20 0.51
▸ FGFR1 P11362 1/20 0.49
▸ CYP2C9 P11712 1/20 0.49
▸ PDGFRA P16234 1/20 0.49
▸ CYP2C19 P33261 1/20 0.49
▸ FLT3 P36888 1/20 0.49
▸ LRRK2 Q5S007 1/20 0.49
▸ HDAC6 Q9UBN7 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15847673 0.95 EGFR (0.59) ABL1EGFRBRAFSRCMAP3K20
SCHEMBL15860119 0.94 MAP3K20 (0.56) ABL1EGFRBRAFSRCMAPK14
SCHEMBL15859839 0.94 EGFR (0.58) ABL1EGFRBRAFMAPK14MAP3K20
SCHEMBL15859948 0.92 EGFR (0.56) ABL1EGFRBRAFMAPK14MAP3K20
SCHEMBL15847641 0.91 EGFR (0.54) ABL1EGFRBRAFSRCMAPK14
SCHEMBL15860121 0.90 MAP3K20 (0.59) ABL1EGFRBRAFMAPK14MAP3K20
SCHEMBL15859881 0.89 BRAF (0.58) EGFRBRAFCSF1RKIT
SCHEMBL15859903 0.89 EGFR (0.60) ABL1EGFRBRAFSRCDDR1
SCHEMBL17321174 0.89 ABL1 (0.56) ABL1EGFRBRAFSRCRET
SCHEMBL17321133 0.89 ABL1 (0.56) ABL1EGFRBRAFSRCRET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9493455-B2 Azaindole derivatives as inhibitors of protein kinases ORIBASE PHARMA (FR) 2016-11-15 — — US disclosed
US-9493455-B2 Azaindole derivatives as inhibitors of protein kinases ORIBASE PHARMA (FR) 2016-11-15 — — US disclosed
US-20150353540-A1 AZAINDOLE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES ORIBASE PHARMA (FR) 2015-12-10 — — US disclosed
US-20150353540-A1 AZAINDOLE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES ORIBASE PHARMA (FR) 2015-12-10 — — US disclosed
WO-2014102378-A1 AZAINDOLE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES ORIBASE PHARMA (FR) 2014-07-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353540-A1 AZAINDOLE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES MAP3K5, MAP3K3, MAP3K20 ABL1 95/4885EGFR 1624/4885BRAF 65/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback